



Do ABC transporters regulate plasma membrane organization?

Ambroise Wu, Karolina Wojtowicz, Stéphane Savary, Yannick Hamon,
Tomasz Trombik

► To cite this version:

Ambroise Wu, Karolina Wojtowicz, Stéphane Savary, Yannick Hamon, Tomasz Trombik. Do ABC transporters regulate plasma membrane organization?. Cellular and Molecular Biology Letters, 2020, 25 (1), 10.1186/s11658-020-00224-x . hal-02997365

HAL Id: hal-02997365

<https://amu.hal.science/hal-02997365>

Submitted on 21 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

INVITED REVIEW

Open Access



Do ABC transporters regulate plasma membrane organization?

Ambroise Wu^{1†}, Karolina Wojtowicz^{1†}, Stephane Savary², Yannick Hamon^{3*} and Tomasz Trombik^{1*}

* Correspondence: hamon@ciml.univ-mrs.fr; tomasz.trombik@uwr.edu.pl

[†]Ambroise Wu and Karolina Wojtowicz contributed equally to this work.

²Aix Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France

³Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland

Full list of author information is available at the end of the article

Abstract

The plasma membrane (PM) spatiotemporal organization is one of the major factors controlling cell signaling and whole-cell homeostasis. The PM lipids, including cholesterol, determine the physicochemical properties of the membrane bilayer and thus play a crucial role in all membrane-dependent cellular processes. It is known that lipid content and distribution in the PM are not random, and their transversal and lateral organization is highly controlled. Mainly sphingolipid- and cholesterol-rich lipid nanodomains, historically referred to as rafts, are extremely dynamic "hot spots" of the PM controlling the function of many cell surface proteins and receptors. In the first part of this review, we will focus on the recent advances of PM investigation and the current PM concept. In the second part, we will discuss the importance of several classes of ABC transporters whose substrates are lipids for the PM organization and dynamics. Finally, we will briefly present the significance of lipid ABC transporters for immune responses.

Keywords: ABC transporter, Plasma membrane, Cholesterol, Phospholipids, Rafts, Membrane (nano)domains

This article was specially invited by the editors and represents work by leading researchers.

Introduction

Lipid arrangements determine the physicochemical nature of cell membranes, choreographing signaling cascades and cell metabolism. Deciphering the mechanisms by which cells control the lateral and transversal membrane organization is of general interest considering that auto-immune, atherogenic, or proliferative pathologies might originate from a dysfunction of the lipid equilibrium in the plasma membrane. This field of research is, however, neglected due to its extreme experimental difficulty when considering living cells under physiological conditions. There are indeed several layers of complexity: (a) diversity-related lipid composition (cholesterol, phospholipids, sphingolipids...), (b) their lateral assembly as areas of variable size and composition, (c) the existence of transient interactive proteins and (d) the asymmetry of the two hemi-membranes. Membrane lipid transporters among the members



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

of the ATP Binding Cassette (ABC) transporter and the P-type ATPase families have been hypothesized to be pivotal in the maintenance of membrane lipid composition homeostasis [1]. Although structurally distinct, these transporters share common features such as their polytopic nature, their high molecular weight, and their cytosolic ATPase activity, fueling their transport activity of lipid compounds (for a majority of them). However, establishing the exact nature of their allosteres is still puzzling, since redundant, indirect, or compensatory activities may obscure experimental readouts as demonstrated for multidrug resistance-associated ABC transporters [2]. This review aims to update on recent advances in the knowledge of membrane organization in living cells and how lipid ABC transporters might be implicated in its homeostasis including their direct (associated with the PM) and indirect (function in lipid metabolism that contributes to changes in the composition of membrane lipids) effects on the plasma membrane.

PM organization: from historical perspectives to recent advances

Over the last 40 years, constant progress has been made to refine the original model of plasma membrane organization, described as the fluid mosaic membrane model by Singer and Nicholson, in 1972 [3]. The plasma membrane was defined as a two-dimensional lipid bilayer (composed of amphiphilic phospholipids) where globular integral proteins were incorporated, which was conceived to unify sparse experimental evidence, contradicting the Davidson-Danielli tri-layer (protein-lipid-protein) model [4]. The fluid-mosaic membrane model incorporated at least two major concepts, which have not been disproved since then, namely the fluidity and dynamics of the membrane components and their mosaic nature, partly based on heterokaryon experiments of human and murine cells [5], whose components diffuse laterally and mix rapidly at physiological temperature. As early as 1976, the fluid mosaic model was enriched by its authors, taking into consideration that the cytoskeleton and extracellular matrix could influence the diffusion of membrane molecules and that ordered, or solid lipid phases could exist [6].

Thus the fluid mosaic model from 1972 was often caricatured as simplistic even though its authors had before everyone else introduced fundamental notions such as the formation of specialized domains of the membrane, allowing the reversible association of proteins or lipids, the sequestration or exclusion of membrane components, and translocation directed by the cytoskeleton [7]. Of course, the biochemical nature of these areas had not been established yet, nor their functional importance. However, at that time, the authors suspected the existence of non-covalent forces between membrane components and the formation of paracrystalline structures, particularly at the tight junction level. Precisely in polarized cells where these junctions separate apical and basolateral membranes, new aspects of the structure of cell membranes have been discovered, leading to the concept of the lipid raft described in the mid-1990s [8, 9]. It had been shown that there was differential lipid trafficking in these cells, where sphingolipids (glycosphingolipids and sphingomyelin) were preferentially apical, while glycerolipids such as phosphatidylcholines were basolateral. The existence of an intracellular sorting center where these apical microdomains composed of packed sphingolipids would be constituted led the authors to postulate the existence of moving platforms created by packing mainly of sphingolipids and cholesterol on which proteins could be selectively included or excluded.

Additionally, it transpires from the studies of artificial biomembranes that lipids can self-associate, conferring a coherent lateral structure. In model membranes, there was

observed a phase separation depending on cholesterol added into a mixture with phosphatidylcholine [10]. This leads to lateral segregation of lipid phases, where the polycyclic steroid core of the cholesterol favors its interaction with extended saturated acyl chains of phospholipids, increasing the membrane rigidity locally while excluding phospholipids with bulky unsaturated acyl chains (review in K. Simons et al., [11]). Sphingolipids that harbor longer and more saturated hydrocarbon chains also interact preferentially with cholesterol. Thus in planar lipid monolayers two coexisting lipid phases are created: a thicker lipid ordered phase (Lo), and a thinner lipid disordered phase (Ld). This was extensively studied by atomic force microscopy and fluorescence microscopy (Lin, W. C et al., [12] as an example). Complexifying lipid composition into ternary mixture broadens our knowledge of membrane lipid segregation (reviewed in Marsh, D [13].) while facing the challenge of recreating *in vitro* the vast diversity of a native plasma membrane, composed of thousands of different lipid species (considering the variability in the length/saturation of acyl chains) and hundreds of various membrane proteins, not to mention the presence of the subcortical actin cytoskeleton.

At that time, the main experimental arguments on the cell plasma membrane rafts were based on the insolubility of glycolipid-enriched complexes to non-ionic detergents such as Triton X-100 at 4 °C, and their flotation property in density gradients [14–16]. How then, to be sure that this method does not itself create these “domains”? Intuitively, apart from the presence of detergents, the temperature is expected to influence the biophysical properties of lipids, and the solvability of proteins, which would divert these “detergent-resistant membranes” (DRM) from the living matter [17]. In retrospect, while the concept provided new experimental directions for the level of organization of the plasma membrane, it was based on potentially questionable analytical methods. In this line, numerous studies have shown that the DRM insolubility may be due not only to its lipid composition but also to the anchoring of proteins to the cytoskeleton [18, 19]. One of the common criticisms expressed regarding the purification temperature could be addressed when other less stringent detergents (e.g. Brij98) made it possible to purify DRMs at physiological temperature [20–23], although showing some notable differences between the methods and the choice of the detergent [24]. Another method emerged, consisting of aggregating these raft lipids with cholera toxin, which binds specifically to GM1 gangliosides, preferentially partitioning in DRMs, and considered as markers of the lipid raft [25]. Stable micrometric platforms were observed in confocal microscopy [25]. However, it was not possible to know whether these aggregated domains were a universal signature of lipid rafts, or whether they were a subspecies of domains, assuming that they existed in physiological conditions without aggregation. As a matter of fact, to know whether these domains existed as stable or dynamic lipid entities and whether they condensed in response to an extracellular signal has always proved to be a challenge. Analysis of the onset of the adaptive immune response in different cells such as T and B lymphocytes has shown in *in vitro* stimulation systems that signaling molecules with membrane patches were aggregated by cholera toxin [25, 26], and co-purified in Triton X-100 insoluble fractions, in an activating condition with soluble antibodies [27]. Once again, experimental limitations at the time did not allow the existence of these lipid rafts to be established unambiguously. The Laurdan lipid probe was also detected in condensed areas of the Jurkat leukemic T cell membrane at the activation sites by beads coated with stimulating antibodies [28, 29]. This probe possesses the property of being

inserted parallel to the phospholipids, without partitioning into ordered rather than disordered liquid phases, but whose spectral properties change if it is inserted into condensed regions of a bilayer. The extrusion of cholesterol by methyl-beta-cyclodextrin inhibited this condensation [30]. But other experimental data using this compound have shown that extracting membrane cholesterol may have an inhibitory effect on signaling phenomena [31], have a negative effect on cell survival [32], or target free cholesterol in non-lipid raft fractions [32]. Methyl-beta-cyclodextrin should be carefully considered as a disturbing agent of the membrane, not devoid of side effects. Taken together, these data seemed to show that rafts could constitute signaling platforms whose aggregation impacts on signal transduction in the immune cells studied (T lymphocytes). However, many contradictory data populate the scientific literature concerning lipid rafts, leading to the questioning of their very existence. One of the recurring questions is whether these lipid domains are only the experimental consequence of observation methods based on their direct or indirect aggregation, and, by extension, whether they exist in the physiological state.


The introduction of advanced biophysical techniques (single-particle tracking, fluorescence correlation spectroscopy (FCS), fluorescence recovery after photobleaching) has provided new arguments for the existence of isolated membrane domains of nanometric size, enriched with cholesterol and sphingolipids, and of a highly dynamic nature [16, 33]. The major advantage of these approaches is that they can be performed on living cells in physiological conditions, minimizing disruptions of cellular systems. It appeared that it was possible to probe the organization of the membrane by measuring the diffusion time as a function of the diameter of the confocal excitation spot [34–36]. This method, called spot variation FCS, has shown, based on experimental measurements and numerical simulations, that FCS diffusion times follow a linear relationship with the illumination surface, but deviate from an affine relationship as in the case of Brownian diffusion [37, 38]. These deviations reflect the nature of the dominant confinement of the molecules observed, either in isolated domains or by a meshwork, mostly referring to the cortical actin cytoskeleton. These results were confirmed at different spatial scales in stimulated emission depletion (STED) FCS and scanning FCS and applied to various biological situations [39–42]. Biophotonic techniques have been the best experimental approach to highlight the existence of dynamic membrane inhomogeneities, together with single-particle tracking (hop diffusion) [43, 44], electron paramagnetic resonance of spin-labeled phospholipids and cholesterol analogues (reviewed in Subczynski, W. K., & Kusumi, A [45].), STED [40, 46] or fluorescence lifetime imaging microscopy (actin asters) [47, 48]. On the one hand, it appears that lipid raft marker molecules, such as glycosylphosphatidylinositol-anchored proteins, are indeed molecules whose diffusion is not purely Brownian [35, 49], ensuring an overall consistency to all these approaches, even if the biochemical nature of their confinement is a matter of debate [50]. What is important to note is that there is not one type, one size, one lifetime of membrane domains, but a multitude of biochemical confinement nature (lipid-lipid, actin domains, lipid-protein, etc.) and that there is not a single type of lipid domain, but each molecule may have its signature type of confined diffusion, based on their interactions, not exclusively with cholesterol and sphingolipids, but also with their local environment. For example, some anionic phospholipids such as phosphatidylserine or polyphosphoinositides (e.g. PIP2 or PIP3) seem to play a role in the

specialization of nanodomains [44], in relation with a structural configuration of the proteins with which they interact [51, 52]. This notion of specialization and diversity, reminiscent of the lipid shell concept [53], would ensure the homeostasis of cellular systems restricting access of reaction patterns to potential interlocutors in the absence of specific activation signals [54, 55].

It has long been tempting to envisage ATP binding cassette (ABC) transporters as master players in lipid rafts and, by extension, plasma membrane organizers. These transporters belong to five different subfamilies (from A to G) and have distinct substrate specificities and subcellular localizations [56].

Cholesterol effluxes in lipid domains may affect membrane lipid organization

On the grounds of their transport function, acting as lipid floppases or membrane lipid exporters, it has been repeatedly suggested that ABC transporters could be such central regulators of the plasma membrane. Few biophysical studies support this view [57]. Most evidence arises from DRM methodologies, consistently showing that ABCA1 is solubilized by Triton X-100 but not ABCG1, whereas apolipoprotein A-I (ApoA-I)-mediated cholesterol effluxes would take place in lipid rafts dependent upon ABCA1 functionality in macrophages [58]. Cholesterol is tightly regulated at the PM, as a result of intracellular trafficking, lateral distribution, and efflux towards plasmatic acceptors. The most widely described phenomenon is indeed cholesterol efflux mediated by ABCA1 and ABCG1 (Fig. 1). ABCA1, the prototype of the ABCA subfamily, is ubiquitously



expressed, tightly regulated by the liver X receptor/retinoid X receptor pathway [59], concomitantly with ABCG1. It has a pivotal role in the removal of cholesterol from peripheral tissues to the liver in the reverse cholesterol transport pathway [60]. Mutations in the *ABCA1* gene lead to a genetic disorder named Tangier disease, whose main hallmarks are low level of high-density lipoprotein (HDL) molecules, the accumulation of cholesterol in peripheric tissues, pronounced atherosclerosis and premature coronary artery disease [61, 62]. It has been shown that ABCA1 drives lipid efflux for HDL biogenesis mediated by the lipidation of lipid poor ApoA-I [63], and this process occurs in the PM lipid rafts [64]. It is unclear nonetheless whether ABCA1 and ApoA-I physically interact despite the fact that chemical cross-linking between ApoA-I and ABCA1 has been evidenced [65]. Another alternative model would be that ApoA-I could interact with the PM in dedicated regions created upon the ABCA1 function [63, 66, 67].

ABCG1 is also a central protein for intracellular sterol homeostasis in a variety of cells, including macrophages, neurons, and endothelial cells. It has been demonstrated that the physiological role of ABCG1 includes cholesterol transport from cells to lipid extracellular acceptors, which is regulated by the liver X receptor/retinoid X receptor pathway [68]. In contrast to ABCA1, ABCG1 promotes sterol efflux to various relatively nonspecific acceptors such as HDL, low-density lipoprotein (LDL), and cyclodextrin, but not to ApoA-I [69]. Although several authors have argued that ABCG1 is mainly localized in endosomes, it is now clear that ABCG1 traffics to the plasma membrane, where it increases the cholesterol cell removal [70, 71], apparently tightly in contact with actin cytoskeleton [72].

Due to its high homology with ABCA1 (54% based on amino acid sequence), ABCA7 was suggested to share with ABCA1 the role of a lipid exporter [73]. However, even if it has been shown that in ABCA7 over-expressing HEK 293 cells the transporter bound to a cholesterol acceptor, ApoA-I, it mediated only the efflux of cellular phospholipids but not cholesterol, whereas ABCA1 mediates both [74], resulting in the generation of mostly cholesterol-poor HDL particles [75]. Moreover, in *ABCA7*^{-/-} mice macrophages phospholipid and cholesterol effluxes did not appear to be altered while ABCA1 loss of function prevented these effluxes [76]. This suggests that ABCA7 plays an accessory role in lipid trafficking compared to ABCA1. However, *ABCA1*-deficient mouse fibroblasts presented higher expression of ABCA7 [77], while *ABCA7*-deficient mouse macrophages displayed an increase of ABCA1 expression [78], implying that ABCA1 and ABCA7 could in certain atypical circumstances compensate the loss of one another.

Other members of the ABCG subfamily have been implicated in sterol transport (Fig. 1), mostly exemplified by the ABCG5/8 hemi-transporters, which form a functional heterodimer at the canalicular membrane of hepatocytes and promote biliary excretion of sterols into the gallbladder, being the final bile reservoir [79], and causing sitosterolemia when mutated [80]. ABCG4 is another member of the family of ABCG transporters, which were discovered initially based on the high sequence homology with ABCG1. These proteins are closely related both in amino acid sequence and in specific functions such as cholesterol efflux to HDL but not to ApoA-I. It has been demonstrated that both ABCG1 and ABCG4 can form a heterodimer and cooperate to remove cellular cholesterol efficiently [81]. Unlike ABCG1, ABCG4 is unresponsive to LXR activation, and its expression concerning cell types and tissues is significantly restricted [68]. ABCG4 is highly expressed in the brain, in particular in neurons or astrocytes,

and it can play an indirect role in Alzheimer's disease, which is related to disrupted cholesterol metabolism and amyloid- β -peptide accumulation [82].

It has been proposed that ABCA1 synergizes sequentially with ABCG1/G4 to increase the formation of HDL and optimize cellular cholesterol efflux. In this context, HDL-like particles formed by the activity of ABCA1 act as acceptors of cholesterol exported by either ABCG1 or ABCG4 proteins. Moreover, the nascent lipoprotein particles produced by ABCA1 are capable of cholesterol removal from cell surface domains formed by either ABCG1 or ABCG4 transporters [81]. All of the mentioned proteins seem to be very important for cholesterol and lipid homeostasis; however, they could modulate various physiological interactions occurring within the plasma membrane and disrupt lipid raft structures, modulating the plasma membrane organization [83].

ABC transporter dependent-phospholipid flopping affects membrane organization

Several mammalian ABC transporters share the property of translocating phospholipids from the inner leaflet to the outer leaflet (floppase activity) with generally poor specificity. This feature probably originates from the very first ABC transporter, P-glycoprotein (ABCB1), conferring to the cells the ability to extrude cytotoxic drugs, mainly hydrophobic, embedded in the plasma membrane. This multidrug resistance property is widely unspecific and encompasses hundreds of different chemical compounds. This broad diversity of extruded compounds is additionally increased if other multidrug resistance genes such as *ABCB4*, *ABCC1*, or *ABCC2* are jointly expressed (in particular in the blood-brain barrier, in the liver or along the gastrointestinal tract). This raises the question to what extent ABC transporters share selectivity as lipid translocators and to what extent transbilayer movements of lipids are directly performed by those transporters in physiological conditions. ABCA1 has been shown to transport phosphatidylcholine (PC), phosphatidylserine (PS) and sphingomyelin (SM) (Fig. 1) from the inner leaflet to the outer leaflet of the plasma membrane [63, 84], which may contribute to local heterogeneity suitable for ApoA-I [85] and cholesterol extraction. Associated with this, in an overexpression system in knockout mice, PS exposure activity was correlated with ABCA1 expression [86]. Formal demonstration of lipid translocation activity in living cells is extremely complicated from a technical point of view. An insight into the ABCA1 mechanism of lipid transport has been described by fluorescence lifetime imaging microscopy experiments providing the first evidence that ABCA1 increases the lipid packing of the outer leaflet, altering cholesterol present in the lipid raft within the plasma membrane [57]. These studies provided strong evidence of the role of ABCA1 in plasma membrane lipid organization. Recently, the ABCA1 cryo-electron microscopy structure has been elucidated, revealing a narrow, elongated tunnel formed by the ABCA1 extracellular domain that could potentially translocate phospholipid through the plasma membrane, thus presenting new insights in ABCA1 mechanisms [87]. However, questions regarding the mechanism of cholesterol translocation still remain unanswered. In our recent study, we demonstrated that ABCA1 facilitates the efflux of membrane cholesterol to amphotericin B (AmB), a polyene antibiotic, leading to the formation of bulk cholesterol-AmB structures out of the cell and thus preventing AmB cytotoxicity [88]. From this observation, we can assume that the ABCA1-mediated cholesterol efflux may operate without any specificity for

extracellular cholesterol acceptors. In this line, ABCA1 would only create a specific lipid microenvironment from which cholesterol molecules might be easily extracted by extracellular acceptors.

Besides sterols, ABCG1 mediates the efflux of various choline phospholipids, preferentially SM, compared with PC (Fig. 1). Moreover, Hirayama and collaborators have shown that the cholesterol efflux by ABCG1 is dependent on the cellular SM level, which can regulate the ATPase activity of the transporter [89]. As SM tends to form complexes with sterols in the outer leaflet of the plasma membrane, it has been suggested that ABCG1 can move SM together with cholesterol, destabilizing the lipid bilayer and altering membrane organization [70, 90]. Since both SM and cholesterol are essential components of lipid rafts within the plasma membrane, it has been proposed that the ABCG1 activity may be connected to the presence of the nanodomains, as mentioned above [91], although definitive evidence is still lacking.

Additionally, other ABC transporters (Fig. 1) have been implicated in lipid homeostasis and transport in specific cell populations such as ABCA8, which stimulates sphingomyelin production in oligodendrocytes and would affect myelin stability [92]. ABCB4 basically flops PC from the inner to the outer leaflet of the hepatocytes canalicular membrane in the liver. It makes this phospholipid available for extraction by bile salts into the canalicular lumen, where it protects membranes of cells facing the biliary tree against these bile salts by reducing the detergent activity of the bile salt micelles [93].

Intracellular ABC transporters affect membrane lipid organization

Besides membrane ABC transporters, it has to be emphasized that several intracellular ABC transporters (Fig. 1) have been shown to affect membrane lipid composition indirectly, and by extension PM lateral organization. For example, ABCA2, highly expressed in the brain, plays a role in sphingolipid homeostasis by modulating the intracellular metabolism of sphingolipids [94, 95]. ABCA2 inactivation in mice leads to an age-related modification of brain lipids, resulting in deficiencies in phosphatidylethanolamine (PE), phosphatidylserine, and sphingomyelin and accumulation of ganglioside GM1. ABCA2 is mainly localized in the late endosome/lysosome compartment and the trans-Golgi network in neurons and oligodendrocytes [96], suggesting that ABCA2 may play a role in intracellular lipid trafficking. ABCA2 has also been found to play a role in cholesterol homeostasis. Indeed, ABCA2 over-expression in CHO cells (CHOA2) led to an increased level of unesterified cholesterol in cytoplasmic and endosome/lysosome vesicles together with reduced LDL-derived cholesterol trafficking to the endoplasmic reticulum for cholesterol esterification. ABCA2 over-expression induces a phenotype similar to cholesterol depletion in cells that sequester unesterified cholesterol into endo-lysosomal compartments to prevent cholesterol trafficking back to the plasma membrane [95], due to an imbalanced ceramide/sphingosine ratio within the intraluminal membrane lipid bilayer. It has been reported that in neuronal Schwann cell lines expressing a high level of ABCA2, ceramide metabolite levels were reduced, whereas sphingosine levels were increased [97]. ABCA2 might, therefore, modulate the ceramide/sphingosine ratio by altering lipid metabolism together with esterification of plasma membrane-derived cholesterol [98].

It should be mentioned that high cholesterol level in the brain leads to release of amyloid β protein, whose extracellular accumulation causes Alzheimer's disease [99].

Different mutations of ABCA2 have been associated with high risk for Alzheimer's disease [100, 101], but up to now, the mechanistic role of ABCA2 in Alzheimer's disease remains unclear.

Another intracellular ABC transporter which affects membrane lipid homeostasis is ABCA3. This transporter is mainly expressed in alveolar type II pneumocytes (AT2) in the lung, intracellularly located in lamellar bodies [102]. These secretory organelles are responsible for the storage of pulmonary surfactant, a mixture of cholesterol, phospholipids, and proteins. ABCA3 has been reported to transport lipids into the lamellar bodies of AT2 cells [103]. Indeed, *in vitro* and *in vivo* studies have demonstrated that ABCA3 is involved in regulation of the transport of cholesterol, phosphatidylglycerol, PC, SM, PE, and PS, and that *ABCA3*^{-/-} mice have shown a loss of pulmonary surfactant in the alveolar space linked to a diminution of lamellar body formation and a reduction of phospholipids in the lung [104]. These studies suggest that ABCA3 directly regulates the lamellar body's membrane lipid composition by lipid flip-flop of phosphatidylcholine [105]. More details on ABCA3 will help to investigate neonatal lung diseases further, as its functional loss leads to death shortly after birth because of a fatal deficiency in surfactant [106].

Peroxisomal ABC transporters and membrane lipid homeostasis

Although peroxisomal ABC transporters have no direct effects on PM organization, they greatly contribute to lipid catabolism, providing substrates for alpha- and beta-oxidation and thus participating in whole lipid metabolism. Within the D subfamily of ABC transporters, three half-transporters called ABCD1, ABCD2, and ABCD3 are expressed at the peroxisomal membrane (Fig. 1), whereas ABCD4, the transporter of cobalamin, is expressed at the lysosomal membrane after translocation from the endoplasmic reticulum [107]. ABCD1 was shown to transport coenzyme A-esters of saturated and monounsaturated very-long-chain fatty acids (VLCFAs, fatty acids with more than 22 carbon atoms), and its defect is linked to X-linked adrenoleukodystrophy (X-ALD), the most frequent peroxisomal disorder [108–110]. ABCD2, the closest homolog of ABCD1, displays a partial functional redundancy with ABCD1 and is also predicted to transport polyunsaturated fatty acids (PUFAs) [111, 112]. ABCD3 was recently associated with congenital bile acid synthesis defect-5 and is thought to transport C27-bile acid intermediates but also dicarboxylic acids and branched-chain fatty acyl-CoAs into the peroxisomal matrix [113]. Of note, beta-oxidation is also part of anabolic reactions leading to the synthesis of PUFAs such as docosahexaenoic acid, one of the most essential fatty acids in nervous tissues.


The impact of peroxisomal ABC transporters, and more extensively of peroxisomal metabolism, on membrane structure and function has largely been overlooked. Peroxisomal defects are associated with alterations in the contents of various lipids of importance for membrane functions: fatty acids, plasmalogens (ether-lipids), cholesterol [114]. The recent understanding that peroxisomes are not only metabolically connected with other cell compartments, but also interact closely with them, underscores the importance of peroxisomes in lipid exchanges and membrane lipid homeostasis [115]. Many peroxisomal disorders are associated with neurodegenerative processes and defects in myelin, a plasma membrane extension produced from oligodendrocytes, which wraps neuron axons [116–118]. Myelin is rich in VLCFAs and plasmalogens, and its lipid

composition depends on fatty acid synthesis but is also very dependent on peroxisome metabolism [119, 120]. Concerning X-ALD, it has long been established that ABCD1 deficiency leads to the accumulation of VLCFAs, cholesteryl esters and also membrane lipids (PC, SM, gangliosides, myelin), as observed in erythrocytes [121, 122], fibroblasts [123], myelin [124] or brain tissues [125, 126] of X-ALD patients. Diagnosis of X-ALD, which was initially based on plasma levels of C26:0, proved to be more accurate when using C26:0-lysoPC quantification from a blood spot [127]. A recent lipidomic study in human fibroblasts with peroxisomal defects, including X-ALD, detailed the accumulation of VLCFAs in phospholipid species (PC and lysoPC, PE, and plasmalogens) [128]. Moreover, brain phospholipids and lysophospholipids from *ABCD1*-deficient mice demonstrated saturated and monounsaturated VLCFA accumulation, mostly at the *sn*-1 position of PC and PE [129]. Interestingly, some increased levels of PUFAs were also observed in PC and PE, while PC with an odd-numbered fatty acyl chain and some species of phosphatidylserine, phosphatidylinositides, and phosphatidylglycerol were less present in *ABCD1*-deficient brain [129]. In X-ALD, besides impaired beta-oxidation and increased elongation, a very slow dissociation rate of VLCFAs from a phospholipid bilayer likely contributes to the VLCFA accumulation in membranes [130]. Concerning ABCD2, the modulation of its expression in stable transfectant hepatoma cell models was also shown to trigger modifications of VLCFA levels in phospholipids [111]. Altogether, these data indicate that peroxisomal ABC transporters, at least ABCD1 and ABCD2, contribute to the content of saturated, monounsaturated, and polyunsaturated VLCFAs in membranes, especially in complex lipids such as sphingolipids and plasmalogens. This accumulation likely changes membrane properties and contributes to the pathogenesis of peroxisomal leukodystrophies [131–133]. Of note, in addition to VLCFA accumulation, a ABCD1 defect was found to contribute to accumulation of cholesterol, another modulator of membrane properties [134–136]. Peroxisomes were indeed shown to interact with ER, lysosomes, mitochondria, and lipid droplets and participate in cholesterol trafficking [137, 138].

ABC transporter-dependent lipid rearrangement and immunity

It remains to be established whether ABC transporters are master planners of dynamic membrane architecture or limited to individual metabolic functions such as cholesterol transport that indirectly affect other signaling pathways. This is extremely important from an immunological point of view, for example, where immune responses have to be tightly controlled, and this control often occurs by the PM-mediated rearrangement of the cell surface receptors between raft and non-raft structures which may control their activity [139, 140]. While lipid membrane organization has been studied in the context of signal transduction in immune cells, in particular in TCR signaling [21, 25, 141, 142, 162], the role of ABC transporters in this process has been poorly addressed. Inactivation of LXR β as a major nuclear receptor controlling cholesterol homeostasis shows a major increase in the proliferation of CD4 and CD8 T lymphocytes, which was associated with abolished regulation of ABCA1 and ABCG1 expression upon CD3-crosslinking [143]. It was further confirmed that ABCG1 negatively controls thymocyte and peripheral T lymphocyte proliferation, correlated with an increase in cholesterol cell content [142]. More recently, ABCA1 and ABCG1 have been shown to play a role in interleukin 4 (IL-4) mediated macrophage activation in tumor-associated

macrophages [144]. In general, ABCA1/G1 negatively regulates IL-23 secretion from macrophages and dendritic cells, controlling hematopoietic stem and multipotential progenitor cell proliferation [145]. Inactivation of the expression of ABCG1 negatively regulates the secretion of IL-4 in invariant natural killer T lymphocyte cells but positively regulates interferon-gamma production [146], while ABCA1 interferes with IL-4 and interferon-gamma-dependent signal transduction in macrophages [147]. Selective inactivation of ABCG1 in regulatory T cells led to downregulation of the mTOR pathway, correlated with intracellular cholesterol accumulation [148]. The invalidation of ABCA1 and ABCG1 in dendritic cells has been proven as instrumental in cholesterol accumulation in those cells, promoting NLRP3 inflammasome activation and autoimmune pathology through the enhanced secretion of IL-6, IL-12, and IL-23 from *ABCA1/ABCG1*-double knock-out dendritic cells [149]. In this view, ABCA1 and ABCG1 seem to be central regulators of innate and adaptive immune responses, although the precise molecular mechanism is still not fully unraveled. It has also been reported that ABCA7 regulates NKT cell function by controlling the CD1d localization into the lipid rafts and proper cytokine release in response to antigen stimulation [150]. Interestingly though, the careful monitoring of the expression of all members of the mouse ABC transporters in selected immune cell populations (Fig. 2, based on the ImmGen consortium RNAseq data [151]) demonstrates that numerous ABC



transporters show a medium to high expression level while having never been experimentally questioned. *ABCG1*, but also *ABCA7*, are highly expressed in different lymphoid and myeloid cell types, while *ABCC5* and *ABCD1* are especially highly expressed in peritoneal macrophages.

Conclusions and perspectives

In conclusion, much remains still to be elucidated on the role of ABC transporters in immunity, especially in association with cell cholesterol homeostasis and membrane organization integrity. Recent advances in the design and application of molecular probes for cholesterol may help to determine more precisely the relationship between ABC transporters and membrane organization in the future [152, 153].

In a more perspective view, an interesting future research direction may concern the relation between PM organization and tumor development. It has already been demonstrated that the PM content and organization are significant in terms of cancer development and metastasis [154]. Expression and function of several integral PM and PM-associated proteins, which are not randomly distributed over the PM but instead confined to cholesterol- and sphingolipid-rich nanodomains, are altered in cancer cells [155–159]. Moreover, it has been shown that cholesterol content in tumor cells is higher than in healthy cells and is accumulated specifically in lipid raft nanodomains [160]. Finally, tumor-derived exosomes, which are now believed to play a crucial role in pre-metastatic cancer niche formation, originate from lipid raft structures [161]. We can, therefore, assume a possible role of different ABC lipid transporters in these processes. For example, a direct link between *ABCA1* and *ABCG1* expression and carcinogenesis was recently demonstrated in an ovarian cancer model, where *ABCA1/G1*-mediated cholesterol efflux from the PM of macrophages promotes tumor progression [144].

Taking all this evidence together, there is no doubt about the importance of the lipid ABC transporters for various cellular processes, and future progress in their investigation is needed to broaden our understanding of single-cell and organism physiology in health and disease.

Abbreviations

ABC: ATP-binding cassette transporter; Amb: Amphotericin B; ApoA-I: Apolipoprotein A1; DRM: Detergent resistant membranes; FCS: Fluorescence correlation spectroscopy; HDL: High-density lipoprotein; IL: Interleukin; LDL: Low-density lipoprotein; LXR: Liver X receptor; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine; PM: Plasma membrane; PS: Phosphatidylserine; PUFAs: Polyunsaturated fatty acids; RXR: Retinoid X receptor; SM: Sphingomyelin; STED: Stimulated emission depletion; VLCFAs: Very long-chain fatty acids; X-ALD: X-Linked adrenoleukodystrophy

Acknowledgments

The authors acknowledge the ImmGen consortium. The authors acknowledge Krystyna Gornicka for proofreading of this manuscript.

Authors' contributions

YH and TT conceptually designed this review article, coordinated and participated in writing and corrections of this manuscript. AW together with KW wrote the sections about cholesterol and phospholipid transporters, while SS wrote the section about peroxisomal transporters. The author(s) read and approved the final manuscript.

Funding

AW and TT acknowledge financial support from the National Science Center of Poland (NCN) under project no. 2016/21/B/NZ3/00343. YH acknowledges the support by institutional grants from INSERM, CNRS and Aix-Marseille University to the CIML; the PICSL imaging facility of the CIML (ImagInn), a member of the national infrastructure France-BioImaging supported by the French National Research Agency (ANR-10-INBS-04); the funding from the Excellence Initiative of Aix-Marseille University - A*MIDEX, a French "Investissements d'Avenir" program. SS acknowledges the French Ministère de l'Enseignement Supérieur et de la Recherche and the University of Bourgogne. KW acknowledges

"BioTechNan", a program of interdisciplinary environmental doctoral studies KNOW in the field of Biotechnology and Nanotechnology.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland. ²Lab. Bio-PeroxIL EA7270, University of Bourgogne Franche-Comté, Dijon, France. ³Aix Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

Received: 19 February 2020 Accepted: 5 May 2020

Published online: 06 July 2020

References

1. Coleman JA, Quazi F, Molday RS. Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. *Biochim Biophys Acta Mol Cell Biol Lipids*. 1831;2013:555–74.
2. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer*. 2018;18:452–64.
3. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. *Science*. 1972;175(80):720–31.
4. Danielli JF, Davson H. A contribution to the theory of permeability of thin films. *J Cell Comp Physiol*. 1935;5:495–508.
5. Frye LD, Edidin M. The rapid intermixing of cell surface antigens after formation of mouse-human Heterokaryons. *J Cell Sci*. 1970;7.
6. Nicolson GL. Transmembrane control of the receptors on normal and tumor cells. I. Cytoplasmic influence over cell surface components. *BBA*. 1976;457:57–108.
7. Nicolson GL. The fluid - mosaic model of membrane structure: still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. *Biochim Biophys Acta Biomembr*. 1838;2014:1451–66.
8. Simons K, Van Meer G. Lipid sorting in epithelial cells. *Biochemistry*. 1988;27:6197–202.
9. Ikonen E, Simons K. Protein and lipid sorting from the trans-Golgi network to the plasma membrane in polarized cells. *Semin Cell Dev Biol*. 1998;9:503–9.
10. Hjort Ipsen J, Karlström G, Mouritsen OG, Wennerström H, Zuckermann MJ. Phase equilibria in the phosphatidylcholine-cholesterol system. *BBA*. 1987;905:162–72.
11. Simons K, Vaz WLC. Model systems, lipid rafts, and cell membranes. *Annu Rev Biophys Biomol Struct*. 2004;33:269–95.
12. Lin WC, Blanchette CD, Ratto TV, Longo ML. Lipid asymmetry in DLPC/DSPC-supported lipid bilayers: a combined AFM and fluorescence microscopy study. *Biophys J*. 2006;90:228–37.
13. Marsh D. Cholesterol-induced fluid membrane domains: a compendium of lipid-raft ternary phase diagrams. *Biochim Biophys Acta Biomembr*. 1788;2009:2114–23.
14. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. *Cell*. 1992;68:533–44.
15. Brown DA, London E. Functions of lipid rafts in biological membranes. *Annu Rev Cell Dev Biol*. 1998;14:111–36.
16. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. *Science*. 2010;327(80):46–50.
17. McIntosh TJ, Vidal A, Simon SA. Sorting of lipids and transmembrane peptides between detergent-soluble bilayers and detergent-resistant rafts. *Biophys J*. 2003;85:1656–66.
18. Seveau S, Eddy RJ, Maxfield FR, Pierini LM. Cytoskeleton-dependent membrane domain segregation during neutrophil polarization. *Mol Biol Cell*. 2001;12:3550–62.
19. von Haller PD, Donohoe S, Goodlett DR, Aebersold R, Watts JD. Mass spectrometric characterization of proteins extracted from Jurkat T cell detergent-resistant membrane domains. *Proteomics*. 2001;1:1010–21.
20. Langlet C, Bernard AM, Drevot P, He HT. Membrane rafts and signaling by the multichain immune recognition receptors. *Curr Opin Immunol*. 2000;12:250–5.
21. Drevot P, Langlet C, Guo XJ, Bernard AM, Colard O, Chauvin JP, et al. TCR signal initiation machinery is pre-assembled and activated in a subset of membrane rafts. *EMBO J*. 2002;21:1899–908.
22. Harder T, Engelhardt KR. Membrane domains in lymphocytes - from lipid rafts to protein scaffolds. *Traffic*. 2004;5:265–75.
23. Cubí R, Matas LA, Pou M, Aguilera J, Gil C. Differential sensitivity to detergents of actin cytoskeleton from nerve endings. *Biochim Biophys Acta Biomembr*. 1828;2013:2385–93.
24. Molnár E, Swamy M, Holzer M, Beck-García K, Worch R, Thiele C, et al. Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. *J Biol Chem*. 2012;287:42664–74.
25. Janes PW, Ley SC, Magee AI. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. *J Cell Biol*. 1999;147:447–61.
26. Zhang W, Trible RP, Samelson LE. LAT palmitoylation: its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation. *Immunity*. 1998;9:239–46.
27. Janes PW, Ley SC, Magee AI, Kabouridis PS. The role of lipid rafts in T cell antigen receptor (TCR) signalling. *Semin Immunol*. 2000;12:23–34.

28. Gaus K, Chklovskia E, Fazekas De St. Groth B, Jessup W, Harder T. Condensation of the plasma membrane at the site of T lymphocyte activation. *J Cell Biol.* 2005;171:121–31.
29. Zech T, Ejsing CS, Gaus K, De Wet B, Shevchenko A, Simons K, et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. *EMBO J.* 2009;28:466–76.
30. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signalling pathways in T lymphocytes. *Eur J Immunol.* 2000;30:954–63.
31. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. *Biochem Biophys Res Commun.* 2004;320:165–9.
32. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. *Biochim Biophys Acta Biomembr.* 1768;2007:1311–24.
33. Kusumi A, Shirai YM, Koyama-Honda I, Suzuki KGN, Fujiwara TK. Hierarchical organization of the plasma membrane: investigations by single-molecule tracking vs. fluorescence correlation spectroscopy. *FEBS Lett.* 2010;584:1814–23.
34. Yechiel E, Edidin M. Micrometer-scale domains in fibroblast plasma membranes. *J Cell Biol.* 1987;105:755–60.
35. Wawrzynieck L, Rignault H, Marguet D, Lenne PF. Fluorescence correlation spectroscopy diffusion laws to probe the submicron cell membrane organization. *Biophys J.* 2005;89:4029–42.
36. Lenne PF, Wawrzynieck L, Conchonaud F, Wurtz O, Boned A, Guo XJ, et al. Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork. *EMBO J.* 2006;25:3245–56.
37. He H-T, Marguet D. Detecting Nanodomains in living cell membrane by fluorescence correlation spectroscopy. *Annu Rev Phys Chem.* 2011;62:417–36.
38. Maiferr S, Hamon Y, Bertaux N, He HT, Marguet D. A user's guide for characterizing plasma membrane subdomains in living cells by spot variation fluorescence correlation spectroscopy. *Methods Cell Biol.* 2017;139:1–22.
39. Petrášek Z, Schwille P. Precise measurement of diffusion coefficients using scanning fluorescence correlation spectroscopy. *Biophys J.* 2008;94:1437–48.
40. Eggeling C, Ringemann C, Medda R, Schwarzmann G, Sandhoff K, Polyakova S, et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. *Nature.* 2009;457:1159–62.
41. Ruprecht V, Wieser S, Marguet D, Schütz GJ. Spot variation fluorescence correlation spectroscopy allows for superresolution chronoscopy of confinement times in membranes. *Biophys J.* 2011;100:2839–45.
42. Blouin CM, Hamon Y, Gonnord P, Boularan C, Kagan J, Viaris de Lesegno C, et al. Glycosylation-dependent IFN- γ R partitioning in lipid and actin Nanodomains is critical for JAK activation. *Cell.* 2016;166:920–34.
43. Sako Y, Kusumi A. Compartmentalized structure of the plasma membrane for receptor movements as revealed by a nanometer-level motion analysis. *J Cell Biol.* 1994;125:1251–64.
44. Fujiwara T, Ritchie K, Murakoshi H, Jacobson K, Kusumi A. Phospholipids undergo hop diffusion in compartmentalized cell membrane. *J Cell Biol.* 2002;157:1071–81.
45. Subczynski WK, Kusumi A. Dynamics of raft molecules in the cell and artificial membranes: approaches by pulse EPR spin labeling and single molecule optical microscopy. *Biochim Biophys Acta.* 1610;2003:231–43.
46. Willig KL, Rizzoli SO, Westphal V, Jahn R, Hell SW. STED microscopy reveals that synaptotagmin remains clustered after synaptic vesicle exocytosis. *Nature.* 2006;440:935–9.
47. Sharma P, Varma R, Sarasij RC, Ira GK, Krishnamoorthy G, et al. Nanoscale Organization of Multiple GPI-anchored proteins in living cell membranes. *Cell.* 2004;116:577–89.
48. Goswami D, Gowrishankar K, Bilgrami S, Ghosh S, Ragupathy R, Chadda R, et al. Nanoclusters of GPI-anchored proteins are formed by cortical actin-driven activity. *Cell.* 2008;135:1085–97.
49. Lasserre R, Guo XJ, Conchonaud F, Hamon Y, Hawchar O, Bernard AM, et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. *Nat Chem Biol.* 2008;4:538–47.
50. Sevcik E, Brameshuber M, Fölser M, Weghuber J, Honigmüller A, Schütz GJ. GPI-anchored proteins do not reside in ordered domains in the live cell plasma membrane. *Nat Commun.* 2015;6.
51. Hilgemann DW, Feng S, Nasuhoglu C. The complex and intriguing lives of PIP2 with ion channels and transporters. *Sci STKE.* 2001;2001.
52. Chouaki-Bennmansour N, Ruminski K, Sartre AM, Phelipot MC, Salles A, Bergot E, et al. Phosphoinositides regulate the TCR/CD3 complex membrane dynamics and activation. *Sci Rep.* 2018;8.
53. Anderson RGW, Jacobson K. Cell biology: A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. *Science.* 2002;296(80):1821–5.
54. Xu C, Gagnon E, Call ME, Schnell JR, Schwieters CD, Carman CV, et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3 ϵ cytoplasmic tyrosine-based motif. *Cell.* 2008;135:702–13.
55. Gagnon E, Schubert DA, Gordo S, Chu HH, Wucherpfennig KW. Local changes in lipid environment of TCR microclusters regulate membrane binding by the CD3 ϵ cytoplasmic domain. *J Exp Med.* 2012;209:2423–39.
56. Neumann J, Rose-Sperling D, Hellmich UA. Diverse relations between ABC transporters and lipids: an overview. *Biochim Biophys Acta Biomembr.* 1859;2017:605–18.
57. Zarubica A, Plazzo AP, Stöckl M, Trombik T, Hamon Y, Müller P, et al. Functional implications of the influence of ABCA1 on lipid microenvironment at the plasma membrane: a biophysical study. *FASEB J.* 2009;23:1775–85.
58. Jin X, Sviridov D, Liu Y, Vaisman B, Addadi L, Remaley AT, et al. ABCA1 (ATP-binding cassette transporter A1) mediates ApoA-I (Apolipoprotein a-I) and ApoA-I mimetic peptide mobilization of extracellular cholesterol microdomains deposited by macrophages. *Arterioscler Thromb Vasc Biol.* 2016;36:2283–91.
59. Rodrigues-lima F, Fensome AC, Josephs M, Evans J, Veldman J, Katan M. Sterol-dependent transactivation of the ABC1 promoted by LXR/RXR. *J Biol Chem.* 2000;44.
60. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. *J Clin Invest.* 1999;104:R25–31.
61. Singaraja RR, Brunham LR, Visscher H, Kastelein JJP, Hayden MR. Efflux and atherosclerosis: The clinical and biochemical impact of variations in the ABCA1 gene. *Arterioscler Thromb Vasc Biol.* 2003;23:1322–32.
62. Ilatan I, Alrasadi K, Ruel I, Alwaili K, Genest J. Effect of ABCA1 mutations on risk for myocardial infarction. *Curr Atheroscler Rep.* 2008;10:413–26.

63. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein a-I and formation of high density lipoprotein particles. *J Biol Chem.* 2007;282:25123–30.
64. Sorci-Thomas MG, Owen JS, Fulp B, Bhat S, Zhu X, Parks JS, et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. *J Lipid Res.* 2012;53:1890–909.
65. Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI. Cross-linking and lipid efflux properties of ApoA-I mutants suggest direct association between ApoA-I helices and ABCA1. *Biochemistry.* 2004;43:2126–39.
66. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABCA1. *J Biol Chem.* 2000;275:33053–8.
67. Phillips MC. Is ABCA1 a lipid transfer protein? *J Lipid Res.* 2018;59:749–63.
68. Tarr PT, Tarling EJ, Bojanic DD, Edwards PA, Baldán Á. Emerging new paradigms for ABCG transporters. *Biochim Biophys Acta* 2009;1791:584–593.
69. Sturek JM, Castle JD, Trace AP, Page LC, Castle AM, Evans-Molina C, et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells. *J Clin Invest.* 2010;120:2575–89.
70. Neufeld EB, O'Brien K, Walts AD, Stonik JA, Malide D, Combs CA, et al. The human ABCG1 transporter mobilizes plasma membrane and late endosomal non-sphingomyelin-associated-cholesterol for efflux and esterification. *Biology (Basel).* 2014;3:866–91.
71. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. *J Biol Chem.* 2005;280:30150–7.
72. Pandzic E, Gelissen IC, Whan R, Barter PJ, Sviridov D, Gaus K, et al. The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments. *Sci Rep.* 2017;7.
73. Kamiński WE, Orsó E, Diederich W, Klucken J, Drobnik W, Schmitz G. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). *Biochem Biophys Res Commun.* 2000;273:532–8.
74. Wang N, Lan D, Gerbold-Giannone M, Linsel-Nitschke P, Jehle AW, Chen W, et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein a-I and mediates cellular phospholipid but not cholesterol efflux. *J Biol Chem.* 2003;278:42906–12.
75. Hayashi M, Abe-Dohmae S, Okazaki M, Ueda K, Yokoyama S. Heterogeneity of high density lipoprotein generated by ABCA1 and ABCA7. *J Lipid Res.* 2005;46:1703–11.
76. Linsel-Nitschke P, Jehle AW, Shan J, Cao G, Bacic D, Lan D, et al. Potential role of ABCA7 in cellular lipid efflux to apoA-I. *J Lipid Res.* 2005;46:86–92.
77. Iwamoto N, Abe-Dohmae S, Sato R, Yokoyama S. ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis. *J Lipid Res.* 2006;47:1915–27.
78. Meurs I, Calpe-Berdiel L, Habets KLL, Zhao Y, Korporaal SJA, Mommaas AM, et al. Effects of deletion of macrophage ABCA7 on lipid metabolism and the development of atherosclerosis in the presence and absence of ABCA1. *PLoS One.* 2012;7:e30984.
79. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β. *J Biol Chem.* 2002;277:18793–800.
80. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science.* 2000;290(80):1771–5.
81. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. *J Lipid Res.* 2006;47:2433–43.
82. Dodacki A, Wortman M, Saubaméa B, Chasseigneaux S, Nicolic S, Prince N, et al. Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide. *Sci Rep.* 2017;7.
83. Sano O, Ito S, Kato R, Shimizu Y, Kobayashi A, Kimura Y, et al. ABCA1, ABCG1, and ABCG4 are distributed to distinct membrane Meso-domains and disturb detergent-resistant domains on the plasma membrane. *PLoS One.* 2014;9:e109886.
84. Quazi F, Molday RS. Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants. *J Biol Chem.* 2013;288:34414–26.
85. Chambenoit O, Hamon Y, Marguet D, Rigneault H, Rosseneu M, Chimini G. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. *J Biol Chem.* 2001;276:9955–60.
86. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, Chaslin S, et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. *Nat Cell Biol.* 2000;2:399–406.
87. Qian H, Zhao X, Cao P, Lei J, Yan N, Gong X. Structure of the human lipid exporter ABCA1. *Cell.* 2017;169(7):1228–39.e10. <https://doi.org/10.1016/j.cell.2017.05.020>. Epub 2017 Jun 8.
88. Wu A, Grela E, Wójcikowicz K, Filipczak N, Hamon Y, Luchowski R, et al. ABCA1 transporter reduces amphotericin B cytotoxicity in mammalian cells. *Cell Mol Life Sci.* 2019;1–16.
89. Hirayama H, Kimura Y, Kioka N, Matsuo M, Ueda K. ATPase activity of human ABCG1 is stimulated by cholesterol and sphingomyelin. *J Lipid Res.* 2013;54:496–502.
90. Kobayashi A, Takanezawa Y, Hirata T, Shimizu Y, Misasa K, Kioka N, et al. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. *J Lipid Res.* 2006;47:1791–802.
91. Sano O, Kobayashi A, Nagao K, Kumagai K, Kioka N, Hanada K, et al. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. *J Lipid Res.* 2007;48:2377–84.
92. Kim WS, Hsiao JHT, Bhattacharya S, Glaros EN, Don AS, Tsuruoka S, et al. ABCA8 stimulates sphingomyelin production in oligodendrocytes. *Biochem J.* 2013;452:401–10.
93. Oude Elferink RPJ, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). *Pflügers Arch Eur J Physiol.* 2007;453:601–10.
94. Sakai H, Tanaka Y, Tanaka M, Ban N, Yamada K, Matsumura Y, et al. ABCA2 deficiency results in abnormal sphingolipid metabolism in mouse brain. *J Biol Chem.* 2007;282:19692–9.
95. Mack JT, Townsend DM, Beljanski V, Tew KD. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. *Curr Drug Metab.* 2007;8:47–57.

96. Zhou C-J, Zhao L-X, Inagaki N, Guan J-L, Nakajo S, Hirabayashi T, et al. ATP-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for Oligodendrocytes but not for myelin sheaths. *J Neurosci*. 2001;21:849–57.
97. Davis W Jr. The ATP-binding cassette transporter-2 (ABCA2) regulates cholesterol homeostasis and low-density lipoprotein receptor metabolism in N2a neuroblastoma cells. *Biochim Biophys Acta*. 1811;2011:1152–64.
98. Porn MI, Slotte JP. Reversible effects of sphingomyelin degradation on cholesterol distribution and metabolism in fibroblasts and transformed neuroblastoma cells. *Biochem J*. 1990;271:121–6.
99. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. *Neurobiol Aging*. 2004;25:5–18 author reply 49–62.
100. Macé S, Cousin E, Ricard S, Génin E, Spanakis E, Lafargue-Soubigou C, et al. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. *Neurobiol Dis*. 2005;18:119–25.
101. Wollmer MA, Kapaki E, Hersberger M, Muntwyler J, Brunner F, Tsolaki M, et al. Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. *Am J Med Genet Part B Neuropsychiatr Genet*. 2006;141B:534–6.
102. Yamano G, Funahashi H, Kawanami O, Zhao L-X, Ban N, Uchida Y, et al. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells¹. *FEBS Lett*. 2001;508:221–5.
103. Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H, et al. ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. *J Biol Chem*. 2007;282:9628–34.
104. Cheong N, Zhang H, Madesh M, Zhao M, Yu K, Dodia C, et al. ABCA3 is critical for lamellar body biogenesis in vivo. *J Biol Chem*. 2007;282:23811–7.
105. Matsumura Y, Sakai H, Sasaki M, Ban N, Inagaki N. ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in A549 cells. *FEBS Lett*. 2007;581:3139–44.
106. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. *N Engl J Med*. 2004;350:1296–303.
107. Kawaguchi K, Morita M. ABC transporter subfamily D: distinct differences in behavior between ABCD1-3 and ABCD4 in subcellular localization, function, and human disease. *Biomed Res Int*. 2016;2016.
108. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. *Nature*. 1993;361:726–30.
109. Van Roermund CWT, Visser WF, Ijlst L, Van Cruchten A, Boek M, Kulik W, et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. *FASEB J*. 2008;22:4201–8.
110. Trompier D, Savary S. X-linked adrenoleukodystrophy. Morgan & Claypool; 2013.
111. Genin EC, Geillon F, Gondcaille C, Athias A, Gambert P, Trompier D, et al. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2). *J Biol Chem*. 2011;286:8075–84.
112. Van Roermund CWT, Visser WF, Ijlst L, Waterham HR, Wanders RJA. Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid β-oxidation. *Biochim Biophys Acta*. 2011;1811:148–152.
113. Ferdinandusse S, Jimenez-Sanchez G, Koster J, Denis S, Van Roermund CW, Silva-Zolezzi I, et al. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. *Hum Mol Genet*. 2015;24:361–70.
114. Wanders RJA, Waterham HR. Biochemistry of mammalian peroxisomes revisited. *Annu Rev Biochem*. 2006;75:295–332.
115. Sargsyan Y, Thoms S. Staying in healthy contact: how peroxisomes interact with other cell organelles. *Trends Mol Med*. 2019.
116. Trompier D, Vejux A, Zarrouk A, Gondcaille C, Geillon F, Nury T, et al. Brain peroxisomes. *Biochimie*. 2014;98:102–10.
117. Kassmann CM. Myelin peroxisomes – essential organelles for the maintenance of white matter in the nervous system. *Biochimie*. 2014;98:111–8.
118. Wanders RJA, Poll-The BT. Role of peroxisomes in human lipid metabolism and its importance for neurological development. *Neurosci Lett*. 2017;637:11–7.
119. Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling. *Cell Metab*. 2014;19:380–92.
120. Dimas P, Montani L, Pereira JA, Moreno D, Trötzmüller M, Gerber J, et al. Cns myelination and remyelination depend on fatty acid synthesis by oligodendrocytes. *Elife*. 2019;8.
121. Tsuji S, Suzuki M, Ariga T, Sekine M, Kuriyama M, Miyatake T. Abnormality of long-chain fatty acids in erythrocyte membrane Sphingomyelin from patients with Adrenoleukodystrophy. *J Neurochem*. 1981;36:1046–9.
122. Tanaka K, Shimada M, Naruto T, Yamamoto H, Saeki Y, Sai H, et al. Very long-chain fatty acids in erythrocyte membrane sphingomyelin: detection of ALD hemizygotes and heterozygotes. *Neurology*. 1986;36:791–5.
123. Abe Y, Honsho M, Nakanishi H, Taguchi R, Fujiki Y. Very-long-chain polyunsaturated fatty acids accumulate in phosphatidylcholine of fibroblasts from patients with Zellweger syndrome and acyl-CoA oxidase1 deficiency. *Biochim Biophys Acta*. 2014;1841:610–619.
124. Brown FR, Chen WW, Kirschner DA, Frayer KL, Powers JM, Moser AB, et al. Myelin membrane from Adrenoleukodystrophy brain white matter—biochemical properties. *J Neurochem*. 1983;41:341–8.
125. Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Koilodhy E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. *J Neurochem*. 1976;26:851–60.
126. Wilson R, Sargent JR. Lipid and fatty acid composition of brain tissue from Adrenoleukodystrophy patients. *J Neurochem*. 1993;61:290–7.
127. Huffnagel IC, van de Beek MC, Showers AL, Orsini JJ, Klouwer FCC, Dijkstra IME, et al. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. *Mol Genet Metab*. 2017;122:209–15.
128. Herzog K, Pras-Raves ML, Ferdinandusse S, Verhaar MAT, Luyf ACM, van Kampen AHC, et al. Functional characterisation of peroxisomal β-oxidation disorders in fibroblasts using lipidomics. *J Inher Metab Dis*. 2018;41:479–87.
129. Hama K, Fujiwara Y, Morita M, Yamazaki F, Nakashima Y, Takei S, et al. Profiling and imaging of phospholipids in brains of Abcd1-deficient mice. *Lipids*. 2018;53:85–102.
130. Zhang F, Kamp F, Hamilton JA. Dissociation of long and very long chain fatty acids from phospholipid bilayers. *Biochemistry*. 1996;35:16055–60.

131. Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin: implications for the pathogenesis of adrenoleukodystrophy. *J Clin Invest.* 1995;96:1455–63.
132. Alonso A, Goñi FM. The physical properties of Ceramides in membranes. *Annu Rev Biophys.* 2018;47:633–54.
133. González-Ramírez EJ, Goñi FM, Alonso A. Mixing brain cerebrosides with brain ceramides, cholesterol and phospholipids. *Sci Rep.* 2019;9.
134. Weinhofer I, Forss-Petter S, Kunze M, Žigman M, Berger J. X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism. *FEBS Lett.* 2005;579:5512–6.
135. Chu BB, Liao YC, Qi W, Xie C, Du X, Wang J, et al. Cholesterol transport through lysosome-peroxisome membrane contacts. *Cell.* 2015;161:291–306.
136. Raas Q, Gondcaille C, Hamon Y, Leoni V, Caccia C, Ménétier F, et al. CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy. *Biochim Biophys Acta* 2019;1864:704–714.
137. Xiao J, Luo J, Hu A, Xiao T, Li M, Kong Z, et al. Cholesterol transport through the peroxisome-ER membrane contacts tethered by PI(4,5)P₂ and extended synaptotagmins. *Sci China Life Sci.* 2019;62:1117–35.
138. Yang H. Extended synaptotagmins, peroxisome-endoplasmic reticulum contact and cholesterol transport. *Sci China Life Sci.* 2019;62:1266–9.
139. Owen DM, Gaus K, Magee AI, Cebeauer M. Dynamic organization of lymphocyte plasma membrane: lessons from advanced imaging methods. *Immunology.* 2010;131:1–8.
140. Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, et al. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. *Sci Signal.* 2011;4:ra21–ra21.
141. He HT, Lellouch A, Marguet D. Lipid rafts and the initiation of T cell receptor signaling. *Semin Immunol.* 2005;17:23–33.
142. Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates Thymocyte and peripheral lymphocyte proliferation. *J Immunol.* 2010;184:173–83.
143. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. *Cell.* 2008;134:97–111.
144. Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, et al. Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. *Cell Metab.* 2019;29:1376–89 e4.
145. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. *Cell Stem Cell.* 2012;11:195–206.
146. Sag D, Wingender G, Nowyhed H, Wu R, Gebre AK, Parks JS, et al. ATP-binding cassette transporter G1 intrinsically regulates invariant NKT cell development. *J Immunol.* 2012;189:5129–38.
147. Pradel LC, Mitchell AJ, Zarubica A, Dufort L, Chasson L, Naquet P, et al. ATP-binding cassette transporter hallmarks tissue macrophages and modulates cytokine-triggered polarization programs. *Eur J Immunol.* 2009;39:2270–80.
148. Cheng HY, Gaddis DE, Wu R, McSkimming C, Haynes LD, Taylor AM, et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. *J Clin Invest.* 2016;126:3236–46.
149. Westerterp M, Gautier EL, Ganda A, Molusky MM, Wang W, Fotakis P, et al. Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity. *Cell Metab.* 2017;25:1294–304 e6.
150. Nowyhed HN, Chandra S, Kiosses W, Marcovecchio P, Andary F, Zhao M, et al. ATP binding cassette transporter ABCA7 regulates NKT cell development and function by controlling CD1d expression and lipid raft content. *Sci Rep.* 2017;7:40273.
151. Heng TSP, Painter MW, Elpek K, Lukacs-Kornek V, Mauermann N, Turley SJ, et al. The immunological genome project: networks of gene expression in immune cells. *Nat Immunol.* 2008;9:1091–4.
152. Liu S-L, Sheng R, O'Connor MJ, Cui Y, Yoon Y, Kurilova S, et al. Simultaneous in situ quantification of two cellular lipid pools using orthogonal fluorescent sensors. *Angew Chemie Int Ed.* 2014;53:14387–91.
153. Liu SL, Sheng R, Jung JH, Wang L, Stec E, O'Connor MJ, et al. Orthogonal lipid sensors identify transbilayer asymmetry of plasma membrane cholesterol. *Nat Chem Biol.* 2017;13:268–74.
154. Kampen KR. Membrane proteins: The key players of a Cancer cell. *J Membr Biol.* 2011;242:69–74.
155. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ. Matrix Metalloproteinases in human melanoma. *J Invest Dermatol.* 2000;115:337–44.
156. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. *J Cell Physiol.* 2011;226:2316–28.
157. Zhang Z, Wang L, Du J, Li Y, Yang H, Li C, et al. Lipid raft localization of epidermal growth factor receptor alters matrix metalloproteinase-1 expression in SiHa cells via the MAPK/ERK signaling pathway. *Oncol Lett.* 2016;12:4991–8.
158. Norambuena A, Schwartz MA. Effects of integrin-mediated cell adhesion on plasma membrane lipid raft components and signaling. *Mol Biol Cell.* 2011;22:3456.
159. Raghu H, Sodadasu PK, Malla RR, Gondi CS, Estes N, Rao JS. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. *BMC Cancer.* 2010;10:647.
160. Tosi MR, Tognoli V. Cholestryl esters in malignancy. *Clin Chim Acta.* 2005;359:27–45.
161. Chen T, Guo J, Yang M, Zhu X, Cao X. Chemokine-containing Exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. *J Immunol.* 2011;186:2219–28.
162. Balamuth F, Leitenberg D, Unternaehrer J, Mellman I, Bottomly K. Distinct patterns of membrane microdomain partitioning in Th1 and th2 cells. *Immunity.* 2001;15:729–38.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.